MRC UKALLⅫ／ECOG E2993方案诱导缓解成年人急性淋巴细胞白血病的初步疗效观察

Preliminary observation of efficacy of MRC UKALL Ⅻ/ECOG E2993 regimen for adults with acute lymphoblastic leukemia

目的观察MRC UKALLⅫ／ECOG E2993方案诱导缓解中国成年人急性淋巴细胞白血病（ALL）的疗效和患者不良反应。方法采用MRC UKALLⅫ／ECOG E2993诱导缓解方案治疗初治的11例ALL患者。结果11例患者均达到完全缓解（CR），CR率100％，其中8例患者在第一阶段治疗结束后即达CR。在可随访的8例患者中，5例持续CR，最长生存期30个月，3例复发。该方案骨髓抑制较为强烈，对肝功能有一定影响，主要表现为丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高，经对症治疗后肝功能多可恢复正常。11例患者中无一例因治疗相关死亡。结论MRC UKALLⅫ／ECOG E2993方案适用于中国成年人ALL的诱导化疗。

Objective To observe the efficacy and adverse effects of MRC UKALLⅫ/ECOG E2993 regimen in inducing remission of Chinese adults with acute lymphoblastic leukemia（ALL）. Methods 11 cases of previously untreated ALL patients were treated with MRC UKALLⅫ/ECOG E2993 regimen, then observe the efficacy and adverse effects. Results All of the 11 patients achieved complete remission（CR）, the CR rate was 100 %. Among the 1! patients,8 patients achieved CR after the first course of chemotherapy. In the 8 patients which could be followed up, 5 patients achieved durative CR, among that the longest survival time was 30 months, and 3 patients had relapses. This regimen has a severe myelosuppression. There was an effect on liver function, mostly in the increase of glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase.After the symptomatic treatment, liver function could return to normal. No treatment-related deaths occurred. Conclusion MRC UKALLⅫ/ECOG E2993 regimen can be used as inducing remission therapy for Chinese adults with acute lymphoblastic leukemia.